Business Wire

Avania Bolsters MedTech CRO Value Chain Capabilities With Two Acquisitions in Highly Strategic Areas of Engineering Design & Product Development and Market Access

Share

Avania, a leading, global medical technology contract research organization (CRO), today announced its acquisition of HULL ASSOCIATES LLC and Ironstone Product Development (IPD) with a view toward addressing MedTech’s emerging priorities in regulatory and reimbursement and building scale to offer thoughtful strategies and differentiated project delivery for all product categories.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017266904/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Headquartered in Boston, Massachusetts, HULL ASSOCIATES LLC is a leading strategic market access and reimbursement consultancy firm specialized in achieving market access for medical device, diagnostic, and specialty pharma products in all major global markets, including United States, Europe, Latin America, Japan, India, and China. HULL ASSOCIATES LLC has in-country experts who are specialized in market access, offering both technical knowledge and relationships to achieve results. The core focus areas for the business include strategic services such as market access & reimbursement assessments; evidence planning; data analytics & health economics; pricing analysis; assessment & validation of clinical trial designs; as well as in-country post-launch services to support coverage, coding, and payment in all the global markets.

Founded by Joel Ironstone in 2013 and headquartered in Toronto, Canada, IPD has been focused on assisting clients with all aspects of medical and health product development and commercialization which directly aligns with Avania’s vision. The core focus areas for the business are early product development, quality, and strategic regulatory with projects in the areas of medical robotics and surgical navigation, AI/machine learning, imaging, respiratory devices, IVDs, and wearables. This acquisition will strengthen Avania’s position in these product categories, further advancing Avania’s leadership in this space.

The combined organization offers unmatched high-touch strategic and operational expertise that uniquely drive results for medical device innovators and emerging original equipment manufacturers (OEMs).

“The addition of HULL ASSOCIATES and IPD furthers our vision of becoming a trusted global partner for the MedTech community, advancing innovations from bench to bedside, improving patient outcomes globally,” said Sapna Hornyak, president and CEO of Avania, “and will provide us with enhanced capabilities to bring comprehensive, highly customized solutions to every partnership as we continue to lead the MedTech CRO segment as a preferred life cycle partner.”

Avania customers will benefit from an expanded roster of subject matter experts in the global pre-clinical, clinical (in vitro diagnostics, artificial intelligence/machine learning, and software as medical device), regulatory, and market access consulting space.

About Avania

Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical devices, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being.

About HULL ASSOCIATES LLC

Founded in 2007, HULL ASSOCIATES LLC offers strategic market access and reimbursement consulting to medical device and diagnostic clients in all major global markets. Services include market access & reimbursement assessments; evidence planning; data analytics & health economics; pricing analysis; assessment & validation of clinical trial design and in-country reimbursement strategy and support. The team of in-country experts are specialized in market access with both the technical knowledge and relationships to achieve results.

About Ironstone Product Development (IPD)

Ironstone Product Development (IPD) is an ISO 13485:2016 certified medical device development company. IPD assists clients with all aspects of medical and health product development and commercialization. IPD’s background includes extensive work in engineering, clinical utility and regulatory strategy enabling the team to understand the details of how a product works both technically and clinically while clearly communicating this to regulatory bodies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lindsey Langemeier
SCORR Marketing
+1 402-405-4269
lindsey@scorrmarketing.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting28.2.2024 07:00:00 CET | Press release

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology (AAD) Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio. Galderma’s extensive presence – including two late-breaking presentations on its first-in-class, investigational monoclonal antibody nemolizumab, five oral poster presentations, 16 e-posters, a symposium, and several ‘Meet the Expert’ and interactive booth sessions – highlights its commitment to listening to consumers, patients and healthcare professionals in order to deliver cutting-edge science and innovation that addresses their varied needs. “Our vast presence at AAD combines new data, novel educational activities and patient perspectives, demonstrating how we are putting our commitment to addressing the needs of the dermatology community into action. We particularly look forward to presenting the latest updates from

Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease27.2.2024 22:08:00 CET | Press release

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for axatilimab, an anti-CSF-1R antibody, for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy. The Prescription Drug User Fee Act (PDUFA) date for the FDA decision is August 28, 2024. The BLA is supported by positive data from the AGAVE-201 trial (NCT04710576), recently highlighted in a Plenary Scientific Session at the American Society of Hematology Annual Meeting 2023, which showed that treatment with axatilimab resulted in clinically meaningful results and was generally well-tolerated, with a safety profile that was manageable and consistent with the mechanism of action of CSF-1R inhibition. Axatilimab is being developed by Incyte and Syndax Pharmaceuticals (Nasdaq:SNDX) as part of an exclusive worldwide co-development and co-commercialization license agree

Stonebranch Announces Record-Breaking Growth in 2023, Sets Sights on Future Innovations27.2.2024 19:24:00 CET | Press release

Stonebranch, a leading provider of service orchestration and automation solutions, announced another year of significant growth and innovation. Building on the unprecedented success of 2022, Stonebranch has continued to expand its offerings with major product updates and a host of strategic integrations that solidify its position as a leader in the IT automation industry. New Customer and Partner Relationships Fuel Growth In 2023, Stonebranch significantly expanded its customer base, welcoming a diverse range of new clients from various sectors, including finance, healthcare, manufacturing, and technology. In addition, new technology, channel, and consulting partnerships enhanced Stonebranch’s capabilities and market reach. Reflecting on the company's growth, Stonebranch CEO Giuseppe Damiani stated, "2023 was a pivotal year for Stonebranch. Our ability to attract and retain such a diverse clientele speaks volumes about our users' trust and confidence in our solutions. As organizations

INRED to Provide Wi-Fi Services to Remote Areas in Colombia via SES Satellites27.2.2024 18:06:00 CET | Press release

Following a series of successful collaborations to close the digital divide, Colombian local connectivity service provider INRED and SES announced today they will deliver high-throughput satellite services for Colombia’s Ministry of Information and Communication Technologies (MinTic) to support digital inclusion projects across the country. INRED will utilise SES’s Managed Enterprise service delivered via its Geostationary Earth Orbit (GEO) satellites to connect 300 new sites, including those in remote areas that cannot be reached by traditional, fiber-based terrestrial networks. As part of the project called "Zonas Comunitarias para la Paz", INRED will provide free Wi-Fi services to historically unconnected areas across Colombia via SES’s high throughput SES-17 and SES-14 satellites. The enhanced connectivity services will allow INRED to quickly deliver broadband services to 300 sparsely-populated areas, with the ability to easily scale up capacity in the future if needed. INRED and S

Türk Telekom Achieves the World’s First Mass Deployment of Software-defined Fiber Broadband With Zyxel and Netsia27.2.2024 16:54:00 CET | Press release

Türk Telekom, pioneer of digital transformation Türkiye, has completed the world’s first mass deployment of Software-Defined Fiber Broadband. By using Netsia’s BB Suite and Zyxel’s Whitebox OLT, Türk Telekom has taken an important step towards fulfilling its virtualized and disaggregated broadband network strategy and thus, providing world-class, modern, high quality and high-speed broadband services. “Beyond our role as a telecommunications operator, we are leading Türkiye's ambition to become a significant player in technology exports through our pioneering initiatives and partnerships. While supporting our local ecosystem through collaborations within our country, we are also elevating the prestige and value of our nation through our global endeavors," says Ümit Önal, CEO at Türk Telekom. “The cutting-edge fiber infrastructure technology product Zyxel, developed by Argela, our company renowned for innovative solutions, along with its US subsidiary Netsia, has evolved into an innovat

HiddenA line styled icon from Orion Icon Library.Eye